<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Wong, CW; Fan, YS; Chan, TL; Chan, ASW; Ho, LC; Ma, TKF; Yuen, ST; Leung, SY</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>Journal Of Clinical Pathology, 2005, v. 58 n. 6, p. 640-644</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2005</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/43595">http://hdl.handle.net/10722/43595</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>Journal of Clinical Pathology. Copyright © B M J Publishing Group.; This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs

C W Wong, Y S Fan, T L Chan, A S W Chan, L C Ho, T K F Ma, the Cancer Genome Project, S T Yuen and S Y Leung

doi:10.1136/jcp.2004.022509

Updated information and services can be found at:
http://jcp.bmj.com/cgi/content/full/58/6/640

These include:

References
This article cites 39 articles, 19 of which can be accessed free at:
http://jcp.bmj.com/cgi/content/full/58/6/640#BIBL
1 online articles that cite this article can be accessed at:
http://jcp.bmj.com/cgi/content/full/58/6/640#otherarticles

Rapid responses
You can respond to this article at:
http://jcp.bmj.com/cgi/eletter-submit/58/6/640

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections
Molecular Medicine (1111 articles)
Cancer:other (950 articles)
Dermatology (465 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Journal of Clinical Pathology go to:
http://www.bmjjournals.com/subscriptions/
ORIGINAL ARTICLE

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs

C W Wong, Y S Fan, T L Chan, A S W Chan, L C Ho, T K F Ma, the Cancer Genome Project, S T Yuen, S Y Leung

Background: Malignant melanoma arising from different body compartments may be associated with differing aetiological factors and clinical behaviour, and may manifest diverse molecular genetic profiles. Although many studies have focused on cutaneous melanoma, little is known of mucosal and other types of melanoma. In particular, malignant melanoma of soft parts is different from other melanomas in many respects, yet manifests a common melanocytic differentiation. Mutation of BRAF is now known to be common in cutaneous melanomas, and raises possible new therapeutic options of anti-RAF treatment for these patients. Few data are available for non-cutaneous melanomas.

Aims: To study the incidence of BRAF and NRAS mutations in melanomas arising in diverse internal organs.

Methods: Fifty one melanomas from various internal organs were investigated for BRAF and NRAS mutation by direct DNA sequencing.

Results: BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the aerodigestive and female genital tracts (n = 36). Their occurrence is mutually exclusive, giving a combined mutation incidence rate of 19.4% in mucosal melanomas. Both BRAF and NRAS mutations were absent in malignant melanoma of soft parts (n = 7). BRAF mutation was also absent in uveal melanoma (n = 6), but was seen in two of five cutaneous melanomas. The incidence of BRAF or combined BRAF/NRAS mutations in all non-cutaneous groups was significantly lower than published rates for cutaneous melanomas.

Conclusion: Each melanoma subtype may have a unique oncogenetic pathway of tumour development, and only a small fraction of non-cutaneous melanomas may benefit from anti-RAF treatment.

Melanoma arises from the malignant transformation of pigment producing cells, the melanocytes. Melanocytes originate in the neural crest and migrate to the basal layer of the epidermis and the hair follicles during embryogenesis. Apart from the skin, melanocytes are also found in most squamous covered mucous membranes, the uveal tract in the eye, and the leptomeninges of the brain. Thus, malignant melanoma can be classified by their site of origin into cutaneous melanoma, mucosal melanoma, uveal (ocular) melanoma, and leptomeningeal melanoma. Interestingly, malignant melanoma can also arise in sites not known to harbour melanocytes. The most prominent example includes malignant melanoma of soft parts, also known as clear cell sarcoma of tendons and aponeuroses. This tumour is characterised by nests of malignant cells with a morphological and immunohistochemical profile of melanocytic differentiation, arising in tendons or aponeuroses in the extremities of young adults. Despite a common neural crest origin, the different subtypes of melanoma are distinct in their age of onset, aetiology, and biological behaviour. For example, chromosomal aberrations such as monosomy of chromosome 3 and gain of 8q are common in uveal but rare in cutaneous melanoma. Conversely, alteration of the CDKN2 locus in 9p21 is common in cutaneous but rare in uveal melanoma. The t(12,22)(q13;q12) translocation, resulting in a fusion gene product combining the 5' region of the EWS gene and the 3' region of the ATF1 gene, is found in 80% of malignant melanomas of soft parts, but not in other types of melanoma. Unfortunately, because of their relatively low incidence, genetic changes remain poorly defined for most non-cutaneous melanomas. With the recent development of pathway specific drug targets, defining these genetic changes in various subtypes of melanoma may have important therapeutic implications.

“Interestingly, malignant melanoma can also arise in sites not known to harbour melanocytes”

It has long been known that activation of the RAS–RAF–MEK–ERK–MAPK (mitogen activated protein kinase) pathway plays an important role in cutaneous melanoma development. This involves an activating mutation of NRAS, which is found in over 20% of cutaneous melanomas. More recently, our group has described a high frequency of an activating BRAF mutation (more than 60%) in melanoma cell lines and human tumour samples. BRAF is a serine/threonine kinase that transduces regulatory signals from RAS through MEK to MAPK in the RAS–RAF–MEK–ERK signalling cascade. Subsequent studies by

Abbreviations: MAPK, mitogen activated protein kinase; PCR, polymerase chain reaction; UV, ultraviolet
BRAF mutations in non-cutaneous melanomas

METHODS

Materials

We searched the computerised pathology records of the department of pathology of Queen Mary Hospital and Queen Elizabeth Hospital, Hong Kong from 1993 to 2003. The clinical and pathology records of all patients with a diagnosis of malignant melanoma or malignant melanoma of soft parts (also named clear cell sarcoma of tendon and aponeurosis) were retrieved for review. Patients with a diagnosis of primary non-cutaneous malignant melanoma or metastasis were selected for our present study. All except five cutaneous malignant melanomas or documented metastasis from cutaneous melanoma were excluded. The five cases of cutaneous melanoma or distant metastasis were randomly selected and included as controls for our mutation detection method and potential ethnic differences because most of our patients were of Chinese origin. This study was approved by the ethics committee of the University of Hong Kong.

In total, 56 malignant melanomas from various organ sites were finally selected. Table 1 lists in detail their anatomical site of origin. The histological slides were reviewed and appropriate paraffin wax embedded tissue blocks were retrieved. Sections (6 μm thick) were cut and stained with 0.1% methylene blue. Areas of the malignant melanoma were microdissected under a light microscope for DNA extraction using standard protocols, as described previously.13-15

Mutation detection of BRAF and NRAS

Primers were designed to amplify exons 11 (G loop region) and 15 (activation segment) of BRAF, and exons 1 and 2 of NRAS. The primers for BRAF were the same as those used in our previous study.21 The primer sequences were as follows:

- BRAF exon 11F: 5'-TTCTGGTTGGCCTGAATGCT-3'
- BRAF exon 11R: 5'-ACTGGTCACGATTGCCCACA-3'
- BRAF exon 15F: 5'-TCCTATGCTGGCTCTGATAG-3'
- BRAF exon 15R: 5'-GGGCAAAAAATTATCACTGGAA-3'
- NRAS exon 1F: 5'-GGTTTCCAACAGGTTCTTGC-3'
- NRAS exon 1R: 5'-CAGTGGGCCCTCAATTCTGAT-3'
- NRAS exon 2F: 5'-CACACCCCGAGATTCTTAC-3'
- NRAS exon 2R: 5'-GGCAGAATACACAGAGAAG-3'

Polymerase chain reactions (PCRs) were performed in 20 μl reactions containing 0.5μM of each primer, 2.5mM Mg²⁺, 0.25mM dNTPs, and 1 U of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, California, USA) in 1× PCR buffer. In total, 40 amplification cycles (95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 45 seconds) were performed with an initial denaturation at 95°C for 10 minutes and a final extension at 72°C for 10 minutes. The PCR products were purified with 1 μl Exol/SAP (37°C for 15 minutes, then 85°C for 15 minutes) and were then sequenced directly on both strands using the BigDye® Terminator v1.1 cycle sequencing kit (Applied Biosystems) according to manufacturer’s protocol and analysed by the Applied Biosystems 3730 DNA analyser. All mutations were re-confirmed by independent PCR reactions and direct sequencing.

Table 1 Mutations of BRAF and NRAS in various types of melanoma

<table>
<thead>
<tr>
<th>Site</th>
<th>Mean age (range)</th>
<th>Sample size</th>
<th>No. of mutated BRAF (%)</th>
<th>Nucleotide</th>
<th>Amino acid</th>
<th>No. of mutated NRAS (%)</th>
<th>Nucleotide</th>
<th>Amino acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucosal melanoma</td>
<td>68.1 (33–95)</td>
<td>36</td>
<td>2 (5.6)</td>
<td>T1799A</td>
<td>V600E</td>
<td>5 (13.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head and neck</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>13</td>
<td>1 (7.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maxilla</td>
<td>3</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hard palate or floor of mouth</td>
<td>4</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female genital tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix</td>
<td>1</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vagina</td>
<td>4</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vulva</td>
<td>3</td>
<td>1 (33.3)</td>
<td></td>
<td>A1742T</td>
<td>N581I</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oesophagus</td>
<td>3</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rectum</td>
<td>3</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anus</td>
<td>2</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma of parenchymal organs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>23</td>
<td>1 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovary</td>
<td>48</td>
<td>1 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant melanoma of soft parts</td>
<td>27 (17–38)</td>
<td>7</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uveal melanoma</td>
<td>61 (46–80)</td>
<td>6</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutaneous melanoma</td>
<td>55.6 (40–79)</td>
<td>5</td>
<td>2 (40)</td>
<td>T1799A</td>
<td>V600E</td>
<td>0 (0)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The differences in incidence of BRAF mutations or combined BRAF/NRAS mutations in our series of non-cutaneous melanomas (malignant melanoma of soft parts, mucosal melanoma, and uveal melanoma) were analysed in comparison with the cumulative incidence from all major published series of primary cutaneous malignant melanomas using Fisher’s exact test.

In total, two BRAF mutations were identified in the 36 malignant melanomas arising from the mucosa of the aerodigestive and female genital tract. One mutation was T1799A (V600E) and occurred in a malignant melanoma of the nasopharynx. The other mutation was a novel mutation A1742T (N581I) identified in a vulval malignant melanoma. No BRAF mutation was identified in the seven malignant melanomas of soft parts, six uveal melanomas, or the two melanomas from the ovary and brain. Figure 1 shows representative sequence chromatograms.

Five NRAS mutations were identified in the 36 mucosal melanomas, two involving codon 12 and three involving codon 61. These were from tumours arising from the oesophagus (two cases), nasopharynx (one case), hard palate (one case), or vagina (one case). Two additional NRAS mutations were noted in a uveal melanoma and a melanoma from the brain. None of the malignant melanomas of soft parts harboured an NRAS mutation.

Two BRAF mutations were detected in the five cutaneous melanomas. One mutation, T1799A (V600E), was found in a superficial spreading type melanoma, and the other was a tandem mutation, GT1798-99AA (V600K), occurring in a brain metastasis from a cutaneous melanoma. The three cutaneous melanomas without BRAF mutations were of the acral lentiginous type, the lentigo maligna type, and a melanoma arising from a congenital naevus. No NRAS mutation was detected in the five cutaneous melanomas.

Overall, none of the samples that carried a BRAF mutation had an NRAS mutation.

Table 2 summarises the statistical analysis of differences in incidence of BRAF or combined BRAF/NRAS mutations between the non-cutaneous melanomas from our current series and published series of primary cutaneous melanomas. Both the incidence of BRAF mutation and the combined incidence of BRAF/NRAS mutations were significantly lower in malignant melanoma of soft parts, mucosal melanoma, uveal melanoma, and non-cutaneous melanoma as a group compared with the cutaneous melanomas.

DISCUSSION

We have identified a BRAF mutation in two of 36 mucosal melanomas arising from the aerodigestive and female genital tracts. Maldonado et al previously studied 21 mucosal melanomas and identified two BRAF mutations, whereas Edwards et al studied 13 mucosal melanomas and found no BRAF mutations. Our findings corroborate those of others that BRAF mutation is rare in mucosal melanomas. Although one of the BRAF mutations seen in the mucosal melanomas involved a previously described amino acid substitution in V600 (previously V599), we identified a novel BRAF mutation, N581I, in a vulval melanoma. Mutation involving the same codon but with a different amino acid substitution (N581S, previously N580S) has been reported in a single case of colorectal
cancer. The pathogenic relevance of this novel BRAF mutation awaits further functional characterisation.

NRAS mutation was found in five of 36 mucosal melanomas. This is also comparable to a previous study, which recorded NRAS mutations in four of 28 mucosal melanomas. In our present study, BRAF and NRAS mutations were mutually exclusive; thus, overall, seven of the 36 mucosal melanomas had activation of the RAS–RAF–MEK–ERK–MAPK pathway through either BRAF or NRAS mutation. To our knowledge, this is the first comprehensive study that has characterised both BRAF and NRAS mutations in mucosal melanomas. The combined incidence of BRAF and NRAS mutations is significantly lower (p < 0.0001) than that seen in cutaneous melanomas (table 2).

We found a complete absence of BRAF or NRAS mutations in the seven malignant melanomas of soft parts, which is significantly different from cutaneous melanomas (p < 0.0001). This is the first systematic study of BRAF and NRAS mutation for this type of melanoma. Malignant melanoma of soft parts constitutes a distinct subgroup of malignant melanoma with an intriguing histogenesis and molecular pathway of tumour development. These tumours tend to occur in deep tendons and aponeuroses, where melanocytes are not known to exist normally, and there is no involvement of the overlying skin. They have the same immunohistochemical profile as cutaneous melanomas—expressing the melanocytic markers HMB45 and S100 protein—the latter highlighting their neural crest origin. Intracellular melanin, although scanty, can be demonstrated in more than 50% of cases. The prognosis is generally poor, with a high propensity for recurrence and metastasis. Recurrence may sometimes occur after a long latent period of 10 or more years. The characteristic genetic change in these tumours is the t(12;22)(q13;q12) translocation, resulting in the expression of a fusion EWS–ATF1 transcript, which has not been found in cutaneous melanoma. In this respect, translocation involving the EWS gene is also involved in the development of several sarcomas, including Ewing’s sarcoma and primitive neuroectodermal tumour. BRAF mutations are extremely rare in sarcoma, and were seen in only one of 182 patients with a translocation involving the EWS gene.66 BRAF mutations in malignant melanoma of soft parts do not show BRAF mutation at all.14–17 In contrast, a higher incidence of NRAS mutation was seen in melanoma arising from skin with continuous sun exposure than in skin with intermittent sun exposure or sun protected mucosa.6, 36–37 Although the mutation spectrum in NRAS in many of the cutaneous melanomas is compatible with UV induced mutations—with a hotspot mutation site in codon 610–122

<table>
<thead>
<tr>
<th>Melanoma type</th>
<th>Incidence of BRAF mutation</th>
<th>p Value*</th>
<th>Combined incidence of BRAF/NRAS mutations</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary cutaneous melanoma</td>
<td>178/444 (40.1%)</td>
<td>0.029</td>
<td>111/141 (78.7%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Malignant melanoma of soft parts</td>
<td>0/7 (0%)</td>
<td></td>
<td>0/7 (0%)</td>
<td></td>
</tr>
<tr>
<td>Mucosal melanomas</td>
<td>2/36 (5.6%)</td>
<td></td>
<td>7/36 (19.4%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Uveal melanomas</td>
<td>0/6 (0%)</td>
<td></td>
<td>1/6 (16.7%)</td>
<td>0.0029</td>
</tr>
<tr>
<td>All non-cutaneous melanomas</td>
<td>2/51 (3.9%)</td>
<td></td>
<td>9/51 (17.6%)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*Comparison of each category against primary cutaneous melanomas using Fisher’s exact test.
†Literature data were pooled from the references.

The difference in the incidence of BRAF mutation among different subtypes of malignant melanomas is intriguing. BRAF mutation appears to play an important role in regulating the growth of melanocytes and malignant transformation in the cutaneous compartment. Up to 80% of benign naevi of various histological types, including compound naevi, junctional naevi, and congenital naevi, harbour BRAF mutations. However, it should be noted that most benign naevi are end stage lesions and do not progress to malignant melanoma. In contrast, a study of cutaneous melanoma revealed a low incidence of BRAF mutation (10%) at the radial growth phase, but a high incidence (63%) in the vertical growth phase, which suggests that BRAF mutation does not occur at the initiation of tumorigenesis but is important in the progression of cutaneous melanoma. It has been suggested that the difference in incidence of BRAF mutations in different subtypes of melanoma could be related to aetiological factors such as UV exposure. Accumulating data, including those from the current series, show that the highest incidence of BRAF mutation is found in melanoma that develops in skin subjected to intermittent sun exposure. Melanoma developing in skin with chronic sun damage, in glabrous skin shielded from UV by the cornified layer, and in mucosa totally protected from UV exposure generally has a low incidence of BRAF mutation, in the range of 0–15%. Uveal melanoma and, in this series, melanoma of soft parts do not show BRAF mutation at all.14–17 In contrast, a higher incidence of NRAS mutation was seen in melanoma arising from skin with continuous sun exposure than in skin with intermittent sun exposure or sun protected mucosa.6, 36–37 Although the mutation spectrum in NRAS in many of the cutaneous melanomas is compatible with UV induced mutations—with a hotspot mutation site in codon 610–122

Take home messages

- In contrast to cutaneous melanoma, we found a low incidence of BRAF and NRAS mutations in mucosal melanoma arising from the aerodigestive and female genital tracts, and a complete lack of these mutations in malignant melanoma of soft parts.
- Each subtype of melanoma may have its own unique genetic pathway of development, and only a small proportion of patients with non-cutaneous melanoma may benefit from anti-RAF specific treatment.
involving a TT pyrimidine doublet and its 3’ nucleotide—the most frequent hotspot mutation of BRAF involves a T to A mutation, which is not typical of UV induced mutation. Moreover, a similar mutation spectrum for NRAS genes was found in some of the melanomas arising from internal organs, which are clearly not related to UV exposure. Thus, other environmental or intrinsic biological factors should also be considered as potential causative agents for these mutations in melanomas.

In summary, we have documented a low incidence of BRAF and NRAS mutation in mucosal melanoma arising from the aerodigestive and female genital tracts. Moreover, BRAF and NRAS mutation are totally absent in malignant melanoma of soft parts. These data suggest that each subtype of melanoma may have its own unique genetic pathway of development, and only a small proportion of patients with non-cutaneous melanoma may benefit from anti-RAF specific treatment.

ACKNOWLEDGEMENTS

This work was supported by the Committee on Research and Conference Grant 10205043 from the University of Hong Kong and the Wellcome Trust.

Authors’ affiliations
C W Wong, Y S Fan, T L Chan, A S W Chan, S T Yuen, S Y Leung, Department of Pathology, University of Hong Kong, Queen Mary Hospital, Hong Kong
L C Ho, Department of Pathology, Queen Elizabeth Hospital, Hong Kong
T K F Ma, Department of Pathology, Alice Ho Mui Ling Nethersole Hospital, Hong Kong
Cancer Genome Project, Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK

Competing interest: Members of the Cancer Genome Project are inventors of a patent relating to the development of BRAF for treatment and diagnostics

REFERENCES